Simponi Aria® (golimumab)

Simponi Aria (golimumab) is covered only for FDA‑approved indications (adult rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and adult ankylosing spondylitis) and not for non‑approved uses. Key requirements: initial approval requires specified prior therapy (RA—≥3 months trial of another biologic or a conventional DMARD; JIA—trial of one other agent or documented aggressive disease), prescription/consultation by a rheumatologist (or rheumatologist/dermatologist for PsA), documentation of dosing and prior therapies, initial authorization for 6 months, and reauthorization after ≥6 months with documented objective or symptomatic improvement.

"When requesting Simponi Aria (golimumab), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criter..."